CIRM Funded Clinical Trials

Retinal progenitor cells for treatment of retinitis pigmentosa


Henry Klassen
Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$17,306,668
Trial Sponsor:
Trial Stage: 
Phase 1/2
Trial Status: 
Completed
Targeted Enrollment:
28
ClinicalTrials.gov ID:
Details: 

Retinitis pigmentosa (RP) is a severe form of blindness that runs in families with an incidence of 1:4000. Good target for stem cell therapy due to the defined loss of specific cells. Proposed mechanism: Rescue the light sensing photoreceptors.

Design: 

Open label, single arm study. Intravitreal injection of human retinal progenitor cells in worst seeing eye. Ascending dose (0.5-3M cells) in 2 cohorts.

Goal: 

Safety and efficacy - visual acuity.

Status: 

Completed enrollment and dosing.